MedTrace Logo

The Effects of Commercially Available High Protein Drink on Amino Acid Bioavailability and Recovery From Muscle Fatiguing Exercise in 18-45-year-old Male and Female Participants.

NCT07497113 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2026-03-27

No results posted yet for this study

Summary

Part A = Purpose of study Part A of the BOLT study will focus on characterising the total and essential amino acid concentrations for 4 hours following the consumption of a single serving of: 1) commercially available high-protein yoghurt drink, 2) a micellar casein drink, and 3) a flavoured water-based placebo drink. This is called a bioavailability study.

Part B = Purpose of study Part B of the BOLT study will examine the effect of a twice-daily ingestion of 1) high protein yoghurt drink (test product), or 2) flavoured water based drink (control drink) on biomarkers of 1) muscle damage/stress, 2) physical function, 3) self reported pain and muscle soreness, and 4) range of motion, sleep, and recovery assessments, at 24, 48, and 72 hours following acute muscle fatiguing exercise in 18-45-year-old male and female participants. Participants will be randomly allocated to the test product or control drink groups prior to beginning the first visit.

Conditions

  • Healthy Participants

Interventions

DIETARY_SUPPLEMENT

Commercially available high-protein yoghurt drink

High protein yoghurt drink (1 serving = 25g protein, 300ml),

DIETARY_SUPPLEMENT

Active Comparator: Control drink #1

Micellar casein drink (1 serving = 25g protein, 300 ml),

DIETARY_SUPPLEMENT

Placebo Comparator: Control drink #2

Flavoured water-based placebo drink (1 serving = 0g protein, 300 ml),

Sponsors & Collaborators

  • Danone Global Research & Innovation Center

    collaborator INDUSTRY

  • Anglia Ruskin University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-01
Primary Completion
2025-10-31
Completion
2026-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07497113 on ClinicalTrials.gov